| Name | Lomeguatrib |
| Description | Lomeguatrib (PaTrin-2), a modified guanine base, inhibits the activity of DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (MGMT) . |
| In vitro | In the A375M human melanoma xenograft model, intraperitoneal injection of Lomeguatrib (20 mg/kg) treatment was found to inhibit ATase activity. |
| In vivo | In Raji cells, Lomeguatrib inhibits ATase activity with an IC50 value of 10 nM, while in MCF-7 cells, it effectively inhibits MGMT with an IC50 of 6 nM. |
| Storage | keep away from direct sunlight,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.13 mM), Sonication is recommended. DMSO : 55 mg/mL (168.62 mM), Sonication is recommended.
|
| Keywords | PaTrin2 | PaTrin 2 | O6-alkylguanine-DNA-alkyltransferas | Lomeguatrib | Inhibitor | inhibit | DNMTs | DNAMethyltransferase | DNAAlkylation | DNA MTases | DNA methyltransferase (DNMT) | DNA Methyltransferase | DNA Alkylation |
| Inhibitors Related | Lomustine | Streptozotocin | Levetiracetam | Busulfan | 5-Azacytidine | CBHcy | SW155246 | Zebularine | γ-Oryzanol | Methyl methanesulfonate | Hinokitiol | Carmustine |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |